Thermodynamic Study of Deferiprone Dissolution in Polyethylene Glycol 400 and 2-Propanol Mixture

Document Type : Research Article


1 Student Research Committee, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, I.R. IRAN

2 Pharmaceutical Analysis Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, I.R. IRAN

3 College of Chemistry & Chemical Engineering, Yangzhou University, Yangzhou, Jiangsu 225002, P.R. CHINA

4 Pharmaceutical Analysis Research Pharmaceutical Analysis Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, I.R. IRAN

5 Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, I.R. IRAN

6 Faculty of Pharmacy, Near East University, Nicosia, North Cyprus, Mersin 10, TURKEY


In the current study, the solubility and density of deferiprone were determined in the polyethylene glycol (PEG) 400 and 2-propanol mixtures at 293.2 – 313.2 K using a shake-flask method before a spectrophotometric method. The results showed that the solubility increases with both PEG 400 mass fraction and temperature increase. The measured data were fitted to some mathematical models including van’t Hoff, MRS, Jouyban-Acree, Jouyban-Acree–van’t Hoff, and the modified Wilson models. The results from the investigation of model accuracy showed that there were only tiny differences between measured data and back-calculated data from solubility values (MRD% <3.5%). Moreover, thermodynamic studies showed that the deferiprone dissolution process was endothermic and entropy-driven, and the main contributor of ΔG° was the enthalpy


[1] Hider R.C., Roy S., Ma Y.M., Le Kong X., Preston J., The Potential Application of Iron Chelators for the Treatment of Neurodegenerative Diseases, Metallomics, 3: 239-249 (2011).
[2] Velasco-Sánchez D., Aracil A., Montero R., Mas A., Jiménez L., O’Callaghan M., Tondo M., Capdevila A., Blanch J., Artuch R., Combined Therapy with Idebenone and Deferiprone in Patients with Friedreich’s Ataxia, The Cerebellum, 10: 1-8 (2011).
[3] Cohen A.R., Galanello R., Piga A., De Sanctis V., Tricta F., Safety and Effectiveness of Long-Term Therapy with the Oral Iron Chelator Deferiprone, Blood, 102: 1583-1587 (2003).
[4] Piga A., Roggero S., Salussolia I., Massano D., Serra M., Longo F., “Deferiprone”, Annals of the New York Academy of Sciences, 1202: 75-78 (2010).
[5] Sripetchwandee J., Pipatpiboon N., Chattipakorn N., Chattipakorn S., Combined Therapy of Iron Chelator and Antioxidant Completely Restores Brain Dysfunction Induced by Iron Toxicity, PLoS One, 9: e85115 (2014).
[6] Santacruz K., Lewis J., Spires T., Paulson J., Kotilinek L., Ingelsson M., Guimaraes A., DeTure M., Ramsden M., McGowan E., Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function, Science, 309: 476-481 (2005).
[7] Sikarra D., Shukla V., Kharia A.A., Chatterjee D., Techniques for Solubility Enhancement of Poorly Soluble Drugs: An Overview, JMPAS, 1: 1-22 (2012).
[8] Khan A.D., Singh L., Various Techniques of Bioavailability Enhancement: A Review, JDDT, 6: 34-41 (2016).
[9] Chowdhury M.A., The Applications of Metal-Organic-Frameworks in Controlled Release of Drugs, Rev. J. Chem., 7: 1-22 (2017).
[10] Uylukçuoğlu B., “Chitosan Microspheres and Films Used in Controlled Release”, Middle East Technical University, 2003.
[11] Huang X., Lu D., Ma Y., Zhang L., Wang L., Deng J., Wang Z., Zhao Y., From Small Deferiprone to Macromolecular Micelles: Self-Assembly Enhances Iron Chelation, J Colloid Interface Sci, 533: 375-384 (2019).
[12] Zhang X., Tian Y., Jia J., Zhang T., Zhu G., Synthesis, Characterization and Dissolution of three Pharmaceutical Cocrystals Based on Deferiprone, J. Mol. Struct., 1108: 560-566 (2016).
[13] Rajendrakumar S., Surampudi Venkata Sai Durga A., Balasubramanian S., Strategic Synthon Approach in Obtaining Cocrystals and Cocrystal Polymorphs of a High-Z′ System Deferiprone–an Anti-Thalassemia Drug, Acta Crystallogr. B: Struct. Sci. Cryst. Eng. Mater., 77: 946-964 (2021).
[14] Ain S., Ain Q., Parveen S., An Overview on Various Approaches Used for Solubilization of Poorly Soluble Drugs, Pharm. Res., 2: 84-104 (2009).
[15] Jouyban A., Abbasi M., Rahimpour E., Barzegar-Jalali M., Vaez-Gharamaleki J., Deferiprone Solubility in Some Non-Aqueous Mono-Solvents at Different Temperatures: Experimental Data and Thermodynamic Modelling, Phys. Chem. Liq., 56: 619-626 (2018).
[18] Fathi-Azarbayjani A., Abbasi M., Vaez-Gharamaleki J., Jouyban A., Measurement and COrrelation of DEferiprone SOlubility: Investigation of Solubility Parameter and Application of van't Hoff Equation and Jouyban–Acree Model, J. Mol. Liq., 215: 339-344 (2016).
[20] A. Jouyban, Fakhree M.A.A., In: Acree, Jr. W.E. (Ed.) “Toxicity and Drug Testing”, Intech Co., New York, 2012, Chap. 9.
[21]  Hashemi S.H., Khodadadi A. Dinmohammad M., Solubility Prediction of Etodolac, Lamotrigine, Diazepam, and Clonazepamin in Cosolvent Mixtures Using UNIQUAC, model. IJCCE. 41(6): 2013-2024 (2022).
[22] Alvani-Alamdari S., Rezaei H., Rahimpour E., Hemmati S., Martinez F., Barzegar-Jalali M. Jouyban A., Mesalazine Solubility in the Binary Mixtures of Ethanol and Wate at Various Temperatures, Phys. Chem. Liq. 59(1): 12-25 (2021).
[23] Barzegar-Jalali M., Rahimpour E., Martinez F., Jouyban, A., Solubility and Thermodynamics of Lamotrigine in Carbitol+ Water Mixtures from T=(293.2 to 313.2) K. Chem. Eng. Commun., 206(2): 182-192 (2019).
[24] Grant D., Mehdizadeh M., Chow A.-L., Fairbrother J., Non-Linear Van't Hoff Solubility-Temperature Plots and Their Pharmaceutical Interpretation, Int. J. Pharm., 18: 25-38 (1984).
[25] Jouyban-Gharamaleki A., The modified Wilson Model and Predicting drug Solubility in Water-Cosolvent Mixtures, Chem. Pharm. Bull., 46, 1058-1061 (1998).
[27] Vahdati S., Shayanfar A., Hanaee J., Martínez F., Acree Jr. W.E., A. Jouyban, Solubility of Carvedilol in Ethanol+Propylene Glycol Mixtures at Various Temperatures, Ind. Eng. Chem. Res., 52: 16630-16636 (2013).
[28] Perlovich G.L., Kurkov S.V., Bauer-Brandl A., Thermodynamics of Solutions: II. Flurbiprofen and Diflunisal as Models for Studying Solvation of Drug Substances, Eur. J. Pharm. Sci., 19:, 423-432 (2003).
[29] Kawakami K., Miyoshi K., Ida Y., Impact of the Amount of Excess Solids on Apparent Solubility, Pharm. Res., 22: 1537-1543 (2005).
[30] Baka E., Comer J.E., Takács-Novák K., Study of Equilibrium Solubility Measurement by Saturation Shake-Flask Method Using Hydrochlorothiazide as Model Compound, J. Pharm. Biomed. Anal., 46: 335-341 (2008).
[32] Kale A.R., Kakade S., Bhosale A., A Review on Solubility Enhancement Techniques, Curr. Pharm. Res., 10: 3630-3647 (2020).
[33] Mohammadi S.M., Shayanfar A., Emami S., Jouyban A., Effects of Amount of Excess Solid, the Type of Stirring and Sedimentation Time on Solubility of Sodium Phenytoin and Lamotrigine, ADMET and DMPK, 6: 269-278 (2018).
[34] Jouyban A., Rahimpour E., Karimzadeh Z., A New Correlative Model to Simulate the Solubility of Drugs in Mono-Solvent Systems at Various Temperatures, J. Mol. Liq., 343: 117587 (2021)